{"id":77382,"date":"2024-03-12T09:59:40","date_gmt":"2024-03-12T14:59:40","guid":{"rendered":"https:\/\/equitynewsreport.com\/mckesson-whistleblowers-kickback-lawsuit-is-revived\/"},"modified":"2024-03-12T09:59:40","modified_gmt":"2024-03-12T14:59:40","slug":"mckesson-whistleblowers-kickback-lawsuit-is-revived","status":"publish","type":"post","link":"https:\/\/equitynewsreport.com\/h\/mckesson-whistleblowers-kickback-lawsuit-is-revived\/","title":{"rendered":"McKesson whistleblower’s kickback lawsuit is revived"},"content":{"rendered":"
\n
\n\"McKesson
\n\u00a9 Reuters. <\/span>
\n<\/i>\n<\/div>\n

By Jonathan Stempel<\/p>\n

NEW YORK (Reuters) -A federal appeals court on Tuesday revived a lawsuit by a whistleblower who accused McKesson of providing drug pricing tools to doctors for free, to induce them to buy drugs from the company.<\/p>\n

The 3-0 decision by the 2nd U.S. Circuit Court of Appeals in Manhattan restored state law claims by Adam Hart, a former McKesson business development executive, over tools to help oncologists increase profit margins for prescribed cancer drugs.<\/p>\n

Hart said McKesson offered the tools as a kickback to doctors who agreed to make the Irving, Texas-based pharmaceutical distributor their primary wholesale supplier of branded and generic drugs.<\/p>\n

The Florida resident sued under the federal False Claims Act, saying the kickbacks tainted reimbursement claims submitted to Medicare and Medicaid, and violated a U.S. anti-kickback statute and similar laws of 27 states and Washington, D.C.<\/p>\n

Writing for the appeals court, Circuit Judge Gerard Lynch said Hart fell short of alleging that McKesson willfully broke the federal anti-kickback law.<\/p>\n

Hart’s allegations included that McKesson destroyed documents to conceal its wrongful conduct, and that one executive emailed another about the pricing tools and said: “You didn’t get this from me …. ok?”<\/p>\n

Lynch, however, said a lower court judge erred in finding that Hart’s state law claims, some of which required no proof of willfulness, could survive only if the federal claim survived.<\/p>\n

“The district court erred in dismissing Hart’s state-law claims on the basis that they were premised solely on violations of the federal AKS,” Lynch wrote.<\/p>\n

McKesson and its lawyers did not immediately respond to requests for comment. Hart’s lawyers did not immediately respond to similar requests.<\/p>\n

The appeals court returned Hart’s case to U.S. District Judge Ronnie Abrams in Manhattan.<\/p>\n

False Claims Act cases let whistleblowers pursue claims on behalf of the federal government, and share in recoveries. The U.S. Department of Justice did not intervene in Hart’s case.<\/p>\n

McKesson generated $2.21 billion of profit on $232.6 billion of revenue in the nine months ending Dec. 31.<\/p>\n

The case is U.S. ex rel Hart v McKesson Corp (NYSE:) et al, 2nd U.S. Circuit Court of Appeals, No. 23-726.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

\u00a9 Reuters. By Jonathan Stempel NEW YORK (Reuters) -A federal appeals court on Tuesday revived a lawsuit by a whistleblower who accused McKesson of providing drug pricing tools to doctors for free, to induce them to buy drugs from the company. The 3-0 decision by the 2nd U.S. Circuit Court of Appeals in Manhattan restored state law claims by Adam Hart, a former McKesson business development executive, over tools to help oncologists increase profit margins for prescribed cancer drugs. Hart said McKesson offered the tools as a kickback to doctors who agreed to make the Irving, Texas-based pharmaceutical distributor their […]<\/p>\n","protected":false},"author":5,"featured_media":77383,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[48,49,50,3],"tags":[],"_links":{"self":[{"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/posts\/77382"}],"collection":[{"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/comments?post=77382"}],"version-history":[{"count":0,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/posts\/77382\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/media\/77383"}],"wp:attachment":[{"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/media?parent=77382"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/categories?post=77382"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/tags?post=77382"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}